Arvadatx
The startup has developed a drug platform that identifies specific antibodies linked to abnormal heart rhythms in conditions such as arrhythmogenic right ventricular cardiomyopathy and post-COVID arrhythmias. This technology enables targeted treatment strategies, improving patient outcomes and promoting longer, healthier lives.
Traction –/10
Boston, United States · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a drug platform that identifies specific antibodies linked to abnormal heart rhythms in conditions such as arrhythmogenic right ventricular cardiomyopathy and post-COVID arrhythmias. This technology enables targeted treatment strategies, improving patient outcomes and promoting longer, healthier lives.